Alemtuzumab, CAS 216503-57-0

Product Description: Alemtuzumab (Campath-IH) is a humanized monoclonal antibody against CD52. Alemtuzumab does not cross-react with murine CD52. Alemtuzumab selectively targets the CD52 antigen to induce profound lymphocyte depletion, followed by recovery of T and B cells with regulatory phenotypes. Alemtuzumab is capable of complement-dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity (ADCC), as well as induction of apoptosis. Alemtuzumab has the potential for B-cell chronic lymphocytic leukaemia research[1][2].

Applications: Cancer-programmed cell death

Formula: N/A

References: [1]Kashani N, et al. Immune Regulatory Cell Bias Following Alemtuzumab Treatment in Relapsing-Remitting Multiple Sclerosis. Front Immunol. 2021;12:706278. Published 2021 Oct 28. /[2]Yanping Hu, et al. Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. Immunology. 2009 Oct;128(2):260-70.

CAS Number: 216503-57-0

Molecular Weight: N/A

Compound Purity: 97.15

Research Area: Cancer

Solubility: H2O

Target: Apoptosis

• Artikelnummer: MEXHY-P9948-5
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-P9948-5
• Verpackungseinheit: 5 mg
• Mengeneinheit: STK
• Konjugat: Unconjugated